The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...
Telonic Instruments has added the NoiseKen ESS-PS1 Electrostatic Discharge (ESD) Simulator with the GT-31S ESD Gun. Described as the latest evolution in ESD testing technology, it is engineered for ...
Emmett School District Curriculum & Instruction Coordinator Ramey Uriarte introduced a three-year “Math Improvement Plan” to the Emmett School Board Trustees at a meeting on Monday, Oct. 13, aiming to ...
Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...
A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months. The study involved 198 adults with generalized anxiety disorder, or GAD, a disabling form of anxiety ...
GPP patients have a nearly 5-fold increased mortality risk at 1 year and a 4-fold increased risk over long-term follow-up compared with the general population. The study underscores the need for ...
Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing ...
Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results